PGxO: A very lite ontology to reconcile pharmacogenomic knowledge units
Pierre Monnin, Clement Jonquet, Joël Legrand, Amedeo Napoli, Adrien Coulet

To cite this version:
Pierre Monnin, Clement Jonquet, Joël Legrand, Amedeo Napoli, Adrien Coulet. PGxO: A very lite ontology to reconcile pharmacogenomic knowledge units. Methods, tools & platforms for Personalized Medicine in the Big Data Era, Oct 2017, Palermo, Italy. 10.7287/peerj.preprints.3140v1. hal-01593184v2

HAL Id: hal-01593184
https://inria.hal.science/hal-01593184v2
Submitted on 23 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
PGxO: A very lite ontology to reconcile pharmacogenomic knowledge units

Pierre Monnin\(^1\), Clément Jonquet\(^2\), Joël Legrand\(^1\), Amedeo Napoli\(^1\) and Adrien Coulet\(^1\)

\(^1\)LORIA (CNRS, Inria Nancy-Grand Est, Université de Lorraine), Vandoeuvre-lès-Nancy, France
\(^2\)LIRMM (CNRS, Université de Montpellier), Montpellier, France
\(^3\)BMIR (Stanford University), Stanford, USA

Introduction

In this article, we present a lightweight and simple ontology named PGxO, that we developed to reconcile and trace knowledge in pharmacogenomics (PGx). PGx studies how genomic variations impact variations in drug response phenotypes [4]. Knowledge in PGx is typically composed of units that have the form of ternary relationships \textit{gene variant–drug–adverse event}, stating that an adverse event may occur for patients having the gene variant when being exposed to the drug. For example, one well studied PGx relationship is \textit{G6PD:202A–chloroquine–anemia}, which states that patients with the version 202A of the gene G6PD and treated with chloroquine (an antimalarial drug) may present an anemia (an abnormally low level of red blood cells in blood). These knowledge units \textit{(i)} are available in reference databases, such as PharmGKB [14], reported in the scientific biomedical literature and \textit{(ii)} may be discovered by mining clinical data such as Electronic Health Records (EHRs). Therefore, knowledge in PGx is heterogeneously described \textit{(i.e.,} with various quality, granularity, vocabulary, etc.). It is also increasing: 40,000 PGx relationships were extracted from the 17,000,000 abstracts available on MedLine in 2008 [2] where there are now 27,000,000 abstracts available. It is consequently worth to extract, then compare, assertions from distinct resources.

We manually developed PGxO, by considering only the essential elements that constitute PGx knowledge units (also referred as PGx relationships in this article), and mapped them to existing ontologies. The formalization of pharmacogenomics concepts and relations within PGxO is not a contribution \textit{per se}, as the ontology mainly reuses content represented in previously defined ontologies. However, PGxO originality is to formalize the ternary relationship previously presented and its provenance thus serving as a global schema for reconciling PGx knowledge units of diverse sources. In particular, we will highlight how we encode the provenance of instances of PGx knowledge units using the PROV Ontology (PROV-O) [9]. Accordingly, two instances extracted from two distinct resources are associated with distinct provenances thanks to PROV-O concepts and relations. We propose a set of rules for reconciling knowledge, \textit{i.e.,} for identifying duplicates, or in other terms two instances representing the same knowledge unit. The provenance metadata also allows to associate various quantitative metrics related to PGx relationships such as its level of evidence or the confidence level of the algorithm used to extract the knowledge units. Version and parameters of such algorithms may also be associated, offering the ability to compare outputs of variously tuned executions. By adopting this ontology and defining strict rules for its instantiation, we set up a framework for reconciling, or discerning when necessary, knowledge units reported in, or discovered from various resources. This framework is of importance for the PractiKPharma project, funded by the French National Research Agency, whose goal is to confront PGx knowledge reported in the state of the art \textit{(i.e.,} scientific literature and reference databases) with PGx knowledge discovered from EHRs [3].

Several ontologies have already been developed for pharmacogenomics, but with different purposes, making them inadequate to the present need. In particular, SO-Pharm (Suggested Ontology for Pharmacogenomics) and PO (Pharmacogenomic Ontology) have been developed for knowledge discovery purposes rather than data integration or knowledge reconciliation [1, 6]. The PHARE ontology (for PHarmacogenomic RElationships) has been built for normalizing \textit{gene–drug} and \textit{gene–disease} relationships extracted from texts and is not suitable for representing ternary PGx relationships [2]. More recently, Samwald \textit{et al.} introduced the Pharmacogenomic Clinical Decision Support (or Genomic CDS) ontology, whose main goal is to propose consistent information about pharmacogenomic patient testing to the point of care, to guide physician decisions in clinical practice [12]. We have built PGxO by learning and
adapting from these previous experiences. For consistency reasons and good practices, we mapped PGxO concepts to concepts of these four pre-existing ontologies.

**Methods**

PGxO was developed manually by 3 persons (PM, CJ and AC) in 4 iterations (on June 8th, 2017), following classical ontology construction guidelines [10] and particularly the life cycle of an ontology described in [5]. Accordingly, we achieved the specification, conception, diffusion and evaluation steps of the ontology. In addition, we have connected PGxO to existing ontologies by defining equivalence **mappings**. We also defined **identity rules** which enable to decide when two instances of PGx relationships within the ontology may represent the same knowledge unit.

**Specification.** The scope of PGxO is not to represent all facets of pharmacogenomics, but to represent what we previously defined as PGx knowledge units, i.e., ternary relationships between one (or more) genetic factor, one (or more) drug treatment and one (or more) phenotype; along with their provenance. The objective of PGxO is twofold: reconciling and tracing these PGx knowledge units.

**Conception.** Because of the small size of the ontology, the conception step was realized simultaneously with conceptualization, formalization and implementation steps. PGxO has been implemented in OWL using the Protégé ontology editor.

**Diffusion.** PGxO was originally shared with collaborators of the PractiKPharma project. It is now publicly available on the BioPortal at https://bioportal.bioontology.org/ontologies/PGXO.

**Evaluation / Instantiation.** For the evaluation, we defined **competency questions** as proposed by Gangemi [7]. These questions are "Does PGxO enable to represent a knowledge unit from the PGx state of the art, along with its provenance?", "Does PGxO enables to represent a knowledge unit of PGXO discovered from clinical data, along with its provenance?", "Does PGxO and its associated rules enable to decide if two knowledge units, with distinct provenances, refer to the same thing?". To answer these questions, we have manually instantiated PGxO with examples of knowledge units (along with their provenance). We then define the following rules:

\[
D_1 \equiv D_2 \cap G_1 \equiv G_2 \cap P_1 \equiv P_2 \Rightarrow \{r_1\} \equiv \{r_2\}, \text{i.e., } r_1 \text{ and } r_2 \text{ are referring to the same PGx relationship}
\]

\[
D_1 \subseteq D_2 \cap G_1 \subseteq G_2 \cap P_1 \subseteq P_2 \Rightarrow \{r_1\} \subseteq \{r_2\}, \text{i.e., } r_1 \text{ is more specific than } r_2
\]

\[
(D_1 \subseteq D_2 \cap G_1 \subseteq G_2 \cap P_1 \subseteq P_2 \Rightarrow \{r_1\} \subseteq \{r_2\}, \text{i.e., } r_1 \text{ is more specific than } r_2.
\]

The three previous rules express the eventuality for \( r_1 \) and \( r_2 \) to refer to the same PGx relationship or for one to be more specific than the other. In every other situation, we cannot decide if \( r_1 \) and \( r_2 \), are equivalent or more specific/general.

**Results**

PGxO consists of 9 concepts, 4 relations and 1 necessary condition (i.e., a subsumption axiom). An overview of PGxO concepts and relations is provided as Supplementary Material (SM1). The ontology is organized around the central concept of **PharmacogenomicRelationship**, whose instances may be
Figure 1: Example of instantiation of PGxO with a relationship (warfarin_CYP2C9) and three distinct provenances. Frame A represents the pharmacogenomic relationship. Frames B, C and D represent the three distinct provenances, respectively from PharmGKB, literature and EHRs. In these Frames, the shape of the nodes refers to the type of PROV-O concepts they are instance of. The different types of PROV-O concepts and their associated shapes are listed in the upper right caption. Numeric IDs used in Frames B and C respectively correspond to the PharmGKB annotation identifier and to the PubMed identifier used to extract the PGx relationship.

caused by a GeneticFactor (such as a gene or gene variants), a Drug and causes a Phenotype. For the evaluation of PGxO, we tried answering competency questions by instantiating it with two PGx relationships (warfarin_CYP2C9 and warfarin_CYP2C9_1). The first relationship has three distinct provenances and the second one is a specialization of the first one, with another distinct provenance. Figure 1 represents an extract of PGxO with the instantiation of the warfarin_CYP2C9 relationship (Frame A) and its three distinct provenances (Frames B, C and D).

First, CYP2C9_warfarin was found in PharmGKB with a confidence level “A1”. This provenance is expressed by instantiating PROV-O concepts and relationships as illustrated in Frame B. Second, another PGx relationship was found in SemMed with the same associated drug, gene and phenotype. In this particular case, rule (1) enables to decide that this new instance is equivalent to CYP2C9_warfarin. Accordingly, we associate CYP2C9_warfarin with this new provenance as illustrated in Frame C. Finally, Frame D shows a possible example of clinical data provenance for the same instance. It illustrates the ability of our approach to capture such example, even though we have not run any mining algorithm on a clinical data warehouse yet. A similar PGx relationship was also extracted by FACTA+, but with a more precise adverse event as phenotype. Indeed, FACTA+ proposes a relationship causing heart_block (D006327) is more specific than cardiovascular_diseases (D002318) according to MeSH, therefore rule (2) allows us to identify that we need a new instance of PharmacogenomicRelationship, named here CYP2C9_warfarin_1, to associate this new provenance with. This new instance was specified as more specific than CYP2C9_warfarin (i.e., \{CYP2C9_warfarin_1\} ⊑ \{CYP2C9_warfarin\}). The full instantiation is provided in an OWL file (SM2) and presented in a global figure representing the instantiated ontology (SM3).

In our examples, PGx relationships are expressed using genes. However, our model offers to instantiate PGx relationships involving genomic variations (e.g., variants, haplotypes). Mappings from PGxO
to other PGx ontologies are provided in Supplementary Material SM4, and mappings to large spectrum ontologies in SM5. Among the 9 concepts of PGxO, we were able to map 3 to SO-Pharm, 7 to PHARE, 2 to PO, 2 to Genomic CDS, 7 to MeSH, 7 to NCIt and 6 to SNOMED CT.

Conclusions

In this paper, we presented PGxO, a lightweight ontology for pharmacogenomics, and more importantly, we proposed a set of rules for its instantiation. Using PGxO, one can represent multiple provenances for pharmacogenomic knowledge units, and reconcile duplicates when they come from distinct sources. Thanks to the provided mappings, more expressive ontologies can be leveraged to use the reconciled knowledge in further applications. Because our ontology is minimal and the set of rules reduced, our ontology is easy to understand, adapt and reuse. In the future, we will represent our rules with the SWRL standard [8] and include them in the ontology. Also, we plan to leverage on Semantic Web standards to connect components of PGx knowledge units (e.g., drugs, genes, phenotypes) with Linked Open Data entities elsewhere defined. The main use case of PGxO is to be instantiated by various software agents extracting PGx knowledge from different sources. The resulting knowledge base that we aim at populating within the PractiKPharma project will serve as a framework for confirming or tempering state of the art knowledge in PGx. To this end, our identity rules constitute a very first step.

Supplementary Material

Supplementary material is available at https://github.com/practikpharma/PGxO. It includes:

- SM1: Figure presenting PGxO concepts and relations, ./blob/master/doc/pgxo-overview.pdf
- SM2: An instantiated version of PGxO, ./blob/master/doc/pgxo_with_instances.owl
- SM3: Global figure presenting the instantiation of PGxO, ./blob/master/doc/global-fig.pdf
- SM4: Mappings from PGxO to four ontologies related to PGx, ./blob/master/doc/mapp1.owl
- SM5: Mappings from PGxO to three large spectrum ontologies, ./blob/master/doc/mapp2.owl

References

Acknowledgments

This work is supported by the PractiKPharma project, founded by the French National Research Agency (ANR) under Grant No. ANR-15-CE23-0028, by the Snowball Inria Associate Team, and by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 701771.